Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Vindesine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 12/20 | 0.85 |
| ▸ | TUBB known ✓ | P07437 | 12/20 | 0.85 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 12/20 | 0.85 |
| ▸ | TUBA1B known ✓ | P68363 | 12/20 | 0.85 |
| ▸ | TUBA4A known ✓ | P68366 | 12/20 | 0.85 |
| ▸ | TUBB4B known ✓ | P68371 | 12/20 | 0.85 |
| ▸ | TUBB3 known ✓ | Q13509 | 12/20 | 0.85 |
| ▸ | TUBB2A known ✓ | Q13885 | 12/20 | 0.85 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 12/20 | 0.85 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 12/20 | 0.85 |
| ▸ | TUBA1A known ✓ | Q71U36 | 12/20 | 0.85 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 12/20 | 0.85 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 12/20 | 0.85 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 12/20 | 0.85 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 12/20 | 0.85 |
| ▸ | MLNR | O43193 | 1/20 | 0.96 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.96 |
| ▸ | GHSR | Q92847 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 5/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vindesine SCHEMBL4285 | 1.00 | MLNR (0.96) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL1650601 | 1.00 | MLNR (0.96) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL28250735 | 1.00 | MLNR (0.96) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL28177485 | 1.00 | MLNR (0.96) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL29895728 | 1.00 | MLNR (0.96) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL28186617 | 1.00 | MLNR (0.96) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL11481610 | 0.99 | MLNR (0.95) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL28212242 | 0.99 | MLNR (0.95) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL16553307 | 0.99 | MLNR (0.95) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Vindesine SCHEMBL15866615 | 0.98 | MLNR (1.00) | MLNRPTGS2KCNH2GHSRTUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| US-12311035-B2 | Glymphatic delivery by manipulating plasma osmolarity | UNIVERSITY OF ROCHESTER (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250049881-A1 | FORMULATIONS OF GUANYLATE CYCLSE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2025-02-13 | — | — | US | disclosed |
| US-20250009824-A1 | Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling | KALIVIR IMMUNOTHERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2024-11-19 | — | — | US | disclosed |
| EP-4424697-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Bausch Health Ireland Limited (IE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2024-08-29 | — | — | US | disclosed |
| EP-3004138-B1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20220280423-A1 | GLYMPHATIC DELIVERY BY MANIPULATING PLASMA OSMOLARITY | UNIVERSITY OF ROCHESTER (US) | 2022-09-08 | — | — | US | disclosed |
| CN-108348578-B | Methods for treating myeloproliferative disorders | 阿塞勒隆制药公司 | 2022-08-09 | — | — | CN | disclosed |
| EP-4025251-A1 | METHODS OF TREATMENT USING A GENETICALLY MODIFIED AUTOLOGOUS T-CELL IMMUNOTHERAPY | PACT Pharma, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220152204-A1 | PHOTOIMMUNOTHERAPY AND PHARMACEUTICAL AGENT USED THEREFOR | SHIMADZU CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
| EP-2459167-B2 | SUBCUTANEOUS ANTI-HER2 ANTIBODY FORMULATION | HOFFMANN LA ROCHE (CH) | 2022-03-02 | — | — | EP | disclosed |
| US-20220047672-A1 | COMPOSITIONS AND METHODS INVOLVING LAYILIN | UNIV CALIFORNIA (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3946631-A1 | PHOTOIMMUNOTHERAPY AND PHARMACEUTICAL AGENT USED THEREFOR | Shimadzu Corporation (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20220031867-A1 | GLYMPHATIC DELIVERY BY MANIPULATING PLASMA OSMOLARITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | TUBB4A 3349/4885TUBB 3481/4885TUBA3C 3064/4885 |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | TUBB4A 3349/4885TUBB 3481/4885TUBA3C 3064/4885 |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | TUBB4A 3349/4885TUBB 3481/4885TUBA3C 3064/4885 |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | TUBB4A 3349/4885TUBB 3481/4885TUBA3C 3064/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | TUBB4A 3349/4885TUBB 3481/4885TUBA3C 3064/4885 |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | TUBB4A 3349/4885TUBB 3481/4885TUBA3C 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.